Literature DB >> 25788373

Is hepatitis C subtyping still relevant in the era of direct-acting antiviral therapy?

Mohammed Eslam1, Jacob George.   

Abstract

Mesh：

Substances：

Year:  2014        PMID： 25788373     DOI： 10.1007/s12072-014-9600-2

Source DB:  PubMed          Journal:  Hepatol Int        ISSN： 1936-0533            Impact factor:   6.047


× No keyword cloud information.
  16 in total

Review 1.  How to detect effects: statistical power and evidence-based practice in occupational therapy research.

Authors:  K J Ottenbacher; F Maas
Journal:  Am J Occup Ther       Date:  1999 Mar-Apr

2.  IFNL3 polymorphisms predict response to therapy in chronic hepatitis C genotype 2/3 infection.

Authors:  Mohammed Eslam; Reynold Leung; Manuel Romero-Gomez; Alessandra Mangia; William L Irving; David Sheridan; Ulrich Spengler; Lindsay Mollison; Wendy Cheng; Elisabetta Bugianesi; Duncan McLeod; Abed M Zaitoun; Vito Attino; Diane Goeltz; Jacob Nattermann; Mark Douglas; David R Booth; Jacob George; Golo Ahlenstiel
Journal:  J Hepatol       Date:  2014-04-24       Impact factor: 25.083

Review 3.  Course and outcome of hepatitis C.

Authors:  Jay H Hoofnagle
Journal:  Hepatology       Date:  2002-11       Impact factor: 17.425

4.  Genotype differences in susceptibility and resistance development of hepatitis C virus to protease inhibitors telaprevir (VX-950) and danoprevir (ITMN-191).

Authors:  Ingrid Imhof; Peter Simmonds
Journal:  Hepatology       Date:  2011-04       Impact factor: 17.425

5.  HCV genotype 1 subtypes (1a and 1b): similarities and differences in clinical features and therapeutic outcome.

Authors:  A Andriulli; F Morisco; A M Ippolito; V Di Marco; M R Valvano; M Angelico; G Fattovich; R Granata; A Smedile; M Milella; M Felder; G B Gaeta; P Gatti; M Fasano; G Mazzella; T Santantonio
Journal:  Hepatol Int       Date:  2014-08-13       Impact factor: 6.047

6.  The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection.

Authors:  Jason Grebely; Kimberly Page; Rachel Sacks-Davis; Maarten Schim van der Loeff; Thomas M Rice; Julie Bruneau; Meghan D Morris; Behzad Hajarizadeh; Janaki Amin; Andrea L Cox; Arthur Y Kim; Barbara H McGovern; Janke Schinkel; Jacob George; Naglaa H Shoukry; Georg M Lauer; Lisa Maher; Andrew R Lloyd; Margaret Hellard; Gregory J Dore; Maria Prins
Journal:  Hepatology       Date:  2013-11-22       Impact factor: 17.425

Review 7.  Role of hepatitis C virus genotype 3 in liver fibrosis progression--a systematic review and meta-analysis.

Authors:  A Probst; T Dang; M Bochud; M Egger; F Negro; P-Y Bochud
Journal:  J Viral Hepat       Date:  2011-07-01       Impact factor: 3.728

8.  Hepatitis C virus genotype 1b as a risk factor for hepatocellular carcinoma development: a meta-analysis.

Authors:  Sara Raimondi; Savino Bruno; Mario U Mondelli; Patrick Maisonneuve
Journal:  J Hepatol       Date:  2009-03-20       Impact factor: 25.083

9.  Global distribution and prevalence of hepatitis C virus genotypes.

Authors:  Jane P Messina; Isla Humphreys; Abraham Flaxman; Anthony Brown; Graham S Cooke; Oliver G Pybus; Eleanor Barnes
Journal:  Hepatology       Date:  2014-07-28       Impact factor: 17.425

10.  Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource.

Authors:  Donald B Smith; Jens Bukh; Carla Kuiken; A Scott Muerhoff; Charles M Rice; Jack T Stapleton; Peter Simmonds
Journal:  Hepatology       Date:  2014-01       Impact factor: 17.425
View more
  2 in total

1.  Sofosbuvir/velpatasvir: A promising combination.

Authors:  Aldo Bonaventura; Fabrizio Montecucco
Journal:  World J Hepatol       Date:  2016-07-08

2.  Genotype 1 and 3 Response to Velpatasvir and Sofosbuvir in Chronic Hepatitis C in the Kashmiri Population: An Observational Study.

Authors:  Suresh Gorka; Ghulam M Gulzar; Ghulam N Yattoo; Jaswinder S Sodhi; Gulzar A Dar; Mushtaq A Laway; Saurabh Kaushik; Neeraj Dhar; Syed Mushfiq; Riffat A Aziz
Journal:  J Clin Exp Hepatol       Date:  2019-07-19
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.